vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $11.5M, roughly 1.5× Kymera Therapeutics, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -55.3%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-60.6M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 10.1%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
FVCB vs KYMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $11.5M |
| Net Profit | — | $-76.6M |
| Gross Margin | — | — |
| Operating Margin | 43.7% | -736.8% |
| Net Margin | — | -667.6% |
| Revenue YoY | 4377.5% | -55.3% |
| Net Profit YoY | — | -82.1% |
| EPS (diluted) | $0.31 | $-0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | — | ||
| Q3 25 | $416.0K | — | ||
| Q2 25 | $15.8M | $11.5M | ||
| Q1 25 | $382.0K | $22.1M | ||
| Q4 24 | $378.0K | $7.4M | ||
| Q3 24 | $412.0K | — | ||
| Q2 24 | $415.0K | $25.6M | ||
| Q1 24 | $359.0K | $10.3M |
| Q4 25 | — | — | ||
| Q3 25 | $5.6M | — | ||
| Q2 25 | $5.7M | $-76.6M | ||
| Q1 25 | $5.2M | $-65.6M | ||
| Q4 24 | — | $-70.8M | ||
| Q3 24 | $4.7M | — | ||
| Q2 24 | $4.2M | $-42.1M | ||
| Q1 24 | $1.3M | $-48.6M |
| Q4 25 | 43.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 45.9% | -736.8% | ||
| Q1 25 | — | -336.8% | ||
| Q4 24 | — | -1092.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -198.5% | ||
| Q1 24 | — | -562.2% |
| Q4 25 | — | — | ||
| Q3 25 | 1341.1% | — | ||
| Q2 25 | 36.0% | -667.6% | ||
| Q1 25 | 1352.1% | -296.7% | ||
| Q4 24 | — | -956.9% | ||
| Q3 24 | 1133.3% | — | ||
| Q2 24 | 1001.2% | -164.0% | ||
| Q1 24 | 373.3% | -472.0% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | — | ||
| Q2 25 | $0.31 | $-0.95 | ||
| Q1 25 | $0.28 | $-0.82 | ||
| Q4 24 | $0.27 | $-0.89 | ||
| Q3 24 | $0.25 | — | ||
| Q2 24 | $0.23 | $-0.58 | ||
| Q1 24 | $0.07 | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $335.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $971.5M |
| Total Assets | $2.3B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $335.8M | ||
| Q1 25 | — | $90.0M | ||
| Q4 24 | — | $120.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $67.6M | ||
| Q1 24 | — | $93.5M |
| Q4 25 | $253.6M | — | ||
| Q3 25 | $249.8M | — | ||
| Q2 25 | $243.2M | $971.5M | ||
| Q1 25 | $242.3M | $786.2M | ||
| Q4 24 | $235.4M | $835.6M | ||
| Q3 24 | $230.8M | — | ||
| Q2 24 | $226.5M | $684.9M | ||
| Q1 24 | $220.7M | $711.2M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.2B | $1.1B | ||
| Q1 25 | $2.2B | $918.3M | ||
| Q4 24 | $2.2B | $978.0M | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | $826.0M | ||
| Q1 24 | $2.2B | $868.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-59.9M |
| Free Cash FlowOCF − Capex | $23.8M | $-60.6M |
| FCF MarginFCF / Revenue | 140.7% | -527.9% |
| Capex IntensityCapex / Revenue | 0.3% | 6.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-250.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $3.3M | $-59.9M | ||
| Q1 25 | $5.4M | $-79.2M | ||
| Q4 24 | $18.2M | $-61.8M | ||
| Q3 24 | $4.7M | — | ||
| Q2 24 | $1.6M | $-42.9M | ||
| Q1 24 | $7.2M | $-39.6M |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $3.3M | $-60.6M | ||
| Q1 25 | $5.4M | $-79.6M | ||
| Q4 24 | $18.1M | $-62.7M | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $1.5M | $-47.6M | ||
| Q1 24 | $7.1M | $-47.0M |
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | — | ||
| Q2 25 | 20.8% | -527.9% | ||
| Q1 25 | 1413.6% | -360.3% | ||
| Q4 24 | 4786.0% | -848.3% | ||
| Q3 24 | 1121.8% | — | ||
| Q2 24 | 361.2% | -185.7% | ||
| Q1 24 | 1988.3% | -456.8% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.1% | 6.1% | ||
| Q1 25 | 4.2% | 2.1% | ||
| Q4 24 | 37.3% | 12.7% | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 12.8% | 18.3% | ||
| Q1 24 | 3.9% | 72.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
